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Scleroderma is an autoimmune connective tissue
disease that involves the skin and internal organs for
which there are few reliably effective treatments.1
The cutaneous manifestations of scleroderma
include fibrosis and sclerodactyly, calcinosis cutis,
digital ulcers, pigmentary changes, and mat telangi-
ectasias. Three major pathways are thought to be
important in the pathogenesis of scleroderma: auto-
immunity and inflammation, microvascular alter-
ation, and fibrosis.2 Although immunosuppression
(eg, methotrexate3) and vasodilatory therapy (eg,
nifedipine4) are commonly used to address the
inflammatory and microvascular components,
respectively, therapy directed at tissue fibrosis has
remained elusive. Histone deacetylase inhibitors
(HDACi) may have antifibrogenic effects in the skin
and other organs via mediation of transforming
growth factor beta (TGF-b).5-7 Divalproex sodium
has known activity as an HDACi.8
We report the therapeutic outcome of a patient
treated with the HDACi, divalproex sodium.CASE REPORT
A 62-year-old woman with an 8-year history of
limited scleroderma presented with painful ulcers
involving the fingers that typically recurred every 2
to 4 months. For the previous year she had taken a
stable regimen of rituximab, hydroxychloroquine,
nifedipine, lisinopril, colchicine, aspirin, predni-
sone, and gabapentin. Examination of her skin
revealed pink-red erythema of the hands, peeling
and fissuring of the palms and digits, and mild
tapering of the distal fingers. Treatment with dival-
proex sodium extended release (ER) 250 mg daily
was initiated, and over the next 4 months she did notStony Brook University School of Medicine,a and Department
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Case Reports 2015;1:44-5.experience digital ulcers and reported decreased
swelling of her fingers and improvement in her
ability to grasp objects. During this time the complete
blood cell count with differential, complete meta-
bolic panel, and valproic acid level did not show
hyperglycemia, thrombocytopenia, hepatotoxicity,
abnormally high valproic acid level, or any other
abnormality. The potential benefit of divalproex
sodium was questioned after the development of a
digital pit (although it was smaller and less painful
than her usual ones and appeared to heal more
quickly), and so the medication was discontinued
after 6 months of treatment. Within weeks of
discontinuing divalproex sodium the patient devel-
oped 4 painful digital ulcers (Fig 1, A and B).
Divalproex sodium ER 250 mg daily was restarted,
and the ulcers healed (Fig 1, C andD). One and a half
years later, at the time of writing this report, the
patient continues to take divalproex sodium ER 250
mg daily without a single recurrence of digital ulcers
and with stable improvement in grasp function.
Notably, treatment with divalproex sodium has not
affected her Raynaud’s symptoms or frequency of
attacks.
DISCUSSION
Scleroderma is a complex disease, and although
its pathogenesis is incompletely understood, TGF-b
is thought to be important.2 Immunosuppressive2352-5126
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Fig 1. Scleroderma digital ulcers. Ulcers on the (A) volar
left third digit and (B) the lateral right second digit
occurring within weeks of discontinuation of divalproex
sodium. Re-epithelialization of the ulcers (C and D) after 2
months of therapy.
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stays of therapy, although other agents are often
used.
The use of divalproex sodium in our patient was
based on its properties as an HDACi.8,9 Histone
deacetylase inhibition has been shown to have anti-
fibrogenic effects in the skin and other organs via
mediation of TGF-b.5-7 The HDACi trichostatin A
(TSA) reduced expression of fibrosis-related genes
and blocked the stimulatory effect of TGF-b1 on
procollagen a1 transcription in rat skin fibroblasts
in vitro.6 In another study, the addition of TSA
to nuclear extracts from scleroderma fibroblasts
normalized collagen expression when compared
with normal skin fibroblasts.7 Additionally, treat-
ment of human lung fibroblasts with TSA inhibited
both TGF-b1emediated a-smooth muscle actin
and a1 type I collagen mRNA induction, and
the differentiation of cultured normal human
lung fibroblasts to myofibroblasts was shown
to be an HDAC4-dependent process.5 In another
study of human pulmonary fibroblasts, phenyl-
butyrate, an HDACi, decreased collagen type I
production.10We report remission of digital ulcers in a patient
with limited scleroderma treated with divalproex
sodium. Further evidence of the positive effect of
divalproex sodium in this patient was the recurrence
of ulcers after discontinuing treatment followed
again by remission after restarting treatment.
Divalproex sodium may be beneficial for the
treatment of the digital ulcerations of scleroderma.
We hypothesize that the HDACi activity of dival-
proex sodium, via mediation of TGF-b signaling,5-7
mitigates fibrosis, which contributes to digital ulcers
(together with vasospasm from Raynaud’s and
microvascular alteration). Further studies are neces-
sary to more objectively evaluate the role of dival-
proex sodium in the treatment of scleroderma, and a
clinical trial is currently underway (ClinicalTrials.gov
NCT02166229).
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